Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma

Phase 2 Completed 49 enrolled M.D. Anderson Cancer Center Novartis · collab OSI Pharmaceuticals · collab

NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if RAD001 in combination with Tarceva (erlotinib hydrochloride) can help to control head and neck squamous cell cancer (HNSCC). The safety of this drug combination will also be studied.

Timeline

Start: 2009-07
Primary completion: 2014-11
Completion: 2014-11

Publications

Massarelli E, Lin H, Ginsberg LE, Tran HT, Lee JJ, Canales JR, Williams MD, Blumenschein GR Jr, Lu C, Heymach JV, Kies MS, Papadimitrakopoulou V. Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2015 Jul;26(7):1476-80. doi: 10.1093/annonc/mdv194. Epub 2015 May 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Erlotinib	Small molecule	150 mg	Oral
Subject	Everolimus	Small molecule	5 mg	Oral

Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma

Summary

Timeline

Publications

Drugs

Indications